Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Dublin, May 11, 2026 (GLOBE NEWSWIRE) -- The "Lecanemab Injection Market Report 2026" has been added to ResearchAndMarkets.com's offering. The Lecanemab Injection Market Global Report 2026...
-
Dublin, May 11, 2026 (GLOBE NEWSWIRE) -- The "Mycobax Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. ...
-
HOBOKEN, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- The Hain Celestial Group, Inc. (Nasdaq: HAIN), a leading global health and wellness company whose purpose is to inspire healthier living through...
-
Momcozy Launches NightPro Baby Bottle Warmer, Designed to Make Nighttime Feeding Simpler, Faster, and More Precise
-
Dublin, May 08, 2026 (GLOBE NEWSWIRE) -- The "Incontinence Pads Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F" has been added to ResearchAndMarkets.com's...
-
Dublin, May 07, 2026 (GLOBE NEWSWIRE) -- The "White Oil Market by Grade, Application, and Region - Global Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.The white oil...
-
Delivers Accelerated Revenue Growth, Led by Wipes & Personal Care Achieves Record Gross Margins, Fueled by Powering Honest GrowthReaffirms Full Year 2026 Financial Outlook LOS ANGELES, May 06,...
-
Bel Group Acquires Ingenuity Foods’ Brainiac® Brands to Expand Its Better-For-You Snacking Portfolio
Chicago and New York, May 06, 2026 (GLOBE NEWSWIRE) -- Bel Group, a global player in dairy, fruit, and veggie snacking and the maker of iconic brands Babybel®, GoGo squeeZ®, Boursin®, and The...
-
ZUSDURI™ generated revenue of $29.2 million in Q1 2026, representing 109% quarter-over-quarter growth, reflecting broader utilization with the permanent J Code effective January 1, 2026JELMYTO...
-
Company advances its leadership in MASH with clinical-stage, genetically targeted siRNA asset from Arrowhead PharmaceuticalsPrecision approach targets patients who have a mutation in the PNPLA3 gene,...